Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …

The past decades have witnessed great progress in cancer immunotherapy, which has
profoundly revolutionized oncology, whereas low patient response rates and potential …

Peptide-based materials that have diverse structures and functionalities are an important
type of biomaterials. In former times, peptide-based nanomaterials with excellent stability …

Self-assembly has emerged as an extensively used method for constructing biomaterials
with sizes ranging from nanometers to micrometers. Peptides have been extensively …

Inhibited immune response and low levels of delivery restrict starvation cancer therapy
efficacy. Here, we report on the co-delivery of glucose oxidase (GOx) and indoleamine 2, 3 …

Multiple nanotherapeutics have been approved for patients with cancer, but their effects on
survival have been modest and, in some examples, less than those of other approved …

Nanovesicles and bio-vesicles (BVs) have emerged as promising tools to achieve targeted
cancer therapy due to their ability to overcome many of the key challenges currently being …

Immunotherapy has offered new treatment options for cancer; however, the therapeutic
benefits are often modest and desired to be improved. A semiconducting polymer …

Chemoimmunotherapy is reported to activate a robust T cell antitumor immune response by
triggering immunogenic cell death (ICD), which has initiated a number of clinical trials …

Conspectus Nanomedicine holds significant potential to improve the efficacy of cancer
immunotherapy. Thus far, nanomedicines, ie, 1–100 (0) nm sized drug delivery systems …